Business Update
CV Technologies reports growth strategies
Published in Medical Letter on the CDC and FDA, April 2nd, 2006
Company president, CEO and chief scientific officer Jacqueline Shan unveiled the company's future U.S. growth strategy at its annual general meeting in Edmonton.
The company plans to seek U.S. Food and Drug Administration (FDA) approval for COLD-fX as an OTC (over the counter) drug for the prevention or reduction of the risk of cold and flu. Shan said, "To obtain this approval we plan to conduct phase III drug trials. OTC drug approval will allow us to make very specific medical claims and will afford us label exclusivity which will further enhance our ability to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Cardiovascular Disease
In diabetic adults in the U.S., aspirin use is increasing - Generic Drugs
U.S. FDA approves first generic version of Flonase - Obesity Epidemiology
Body mass index of healthy men is compared with healthy women in U.S. - Proteomics
Hemorrhagic fever virus glycoprotein precursor cleaves to generate new glycoprotein - Virology
Wild-type hepatitis A virus has been stably grown in cell culture - Alzheimer Disease
U.S. NIH report on controlling cardiovascular risk, enhancing cognitive function published - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
